For the year ending 2025-12-31, BTMD had -$15,219K decrease in cash & cash equivalents over the period. $30,179K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenue | 192,219 |
| Cost of revenue | 54,858 |
| General and administrative | 21,582 |
| Marketing expense | 9,526 |
| Employee-related costs | 50,861 |
| Depreciation and amortization | 3,269 |
| Other (income) expense, net | 2,033 |
| Income tax expense | 5,987 |
| Other segment items | 16,572 |
| Net income | 31,597 |
| Depreciation and amortization | 3,670 |
| Bad debt expense | 1,721 |
| Amortization of debt issuance costs | 833 |
| Provision for obsolete inventory | 2,023 |
| Non-cash lease expense | 545 |
| Non-cash interest on share repurchase liability | 3,184 |
| Share-based compensation expense | 8,921 |
| (gain) loss from change in fair value of earnout liabilities | -13,023 |
| Deferred income taxes | 3,975 |
| Accounts receivable | 958 |
| Inventory | 6,242 |
| Other assets | -1,694 |
| Accounts payable | 1,013 |
| Deferred revenue | -400 |
| Accrued expenses | -2,743 |
| Payments pursuant to tra | 93 |
| Operating lease liabilities | -523 |
| Net cash provided by operating activities | 35,194 |
| Purchases of property and equipment | 5,015 |
| Purchases of capitalized software | 1,849 |
| Net cash used in investing activities | -6,864 |
| Repurchases of class a common stock | 3,365 |
| Borrowings on revolving loans | 5,000 |
| Principal repayments on term loan | 6,250 |
| Payments on repurchase liability | 37,581 |
| Proceeds from exercise of stock options | 226 |
| Issuance of stock under purchase plan | 142 |
| Distributions | 1,727 |
| Net cash used in financing activities | -43,555 |
| Effect of exchange rate changes on cash and cash equivalents | 6 |
| Net decrease in cash and cash equivalents | -15,219 |
| Cash and cash equivalents at beginning of period | 39,342 |
| Cash and cash equivalents at end of period | 24,123 |
biote Corp. (BTMD)
biote Corp. (BTMD)